Meticulous Research®, a leading global market research company, published a research report titled, 'South East Asia Pharmaceutical Contract Development and Manufacturing Market by Service {Manufacturing [API, FDF (Parenteral, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing, Packaging}, End User [Large Pharma] - Forecast to 2030.’
Download Free Sample Report@ https://www.meticulousresearch.com/download-sample-report/cp_id=5675?utm_source=pdf&utm_medium=social&utm_campaign=product&utm_content=23-07-2024
According to the latest publication from Meticulous Research®, the South East Asia Pharmaceutical Contract Development and Manufacturing Market is projected to reach $4.2 billion by 2030, growing at a CAGR of 8.3% from 2024 to 2030. This growth is driven by the complex manufacturing requirements of the pharmaceutical industry, increasing investment in pharmaceutical R&D, rising demand for generic medicines and biologics, patent expirations, and increased government funding for drug development and research. Additionally, the growing demand for cell and gene therapies, personalized medicines, and the expansion of high potency active pharmaceutical ingredients (HPAPI) and antibody-drug conjugates (ADC) markets are expected to provide significant growth opportunities. However, the lack of skilled professionals poses a challenge to market growth.
Key Players
The key players in the South East Asia pharmaceutical contract development and manufacturing market include Aenova Group (Germany), Wuxi Biologics, Inc. (China), Vetter Pharma International GmbH (Germany), Catalent, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Almac Group (U.K.), Eurofins Scientific (France), Thermo Fisher Scientific, Inc. (U.S.), Jubilant Life Science Limited (India), Aurobindo Pharma Ltd. (India), APD Pharmaceutical (Singapore), and Esco Aster Pte. Ltd. (Singapore).
Future Outlook
The South East Asia pharmaceutical contract development and manufacturing market is segmented by Type (Pharmaceutical Manufacturing Services {Active Pharmaceutical Ingredient (API) Manufacturing Services and Finished Dosage Forms (FDF) Manufacturing Services [Parenteral/Injectable Manufacturing Services, Tablet Manufacturing Services, Capsule Manufacturing Services, Oral Liquid Manufacturing Services, and Other Formulations]}, Drug Development Services, and Biologics Manufacturing Services{API Manufacturing Services and FDF Manufacturing Services}), End User (Large Pharmaceutical Companies, Small & Mid-Size Pharmaceutical Companies, and Generic Pharmaceutical Companies), and Country. The study also evaluates industry competitors and analyzes their market share at the country level.
Among the types studied, the pharmaceutical manufacturing services segment is expected to hold the largest share of the market in 2024. This segment includes API manufacturing services and FDF manufacturing services, driven by the need to reduce manufacturing costs, accelerate drug market entry, ensure high-quality bulk manufacturing, and meet the growing demand for generic drugs.
The generic pharmaceutical companies segment is expected to register the highest CAGR over the forecast period, driven by increasing competition in the generic market, pricing pressures, and a growing inclination towards using advanced technologies provided by contract development and manufacturing firms.
The report analyzes major countries in South East Asia, including Indonesia, Vietnam, Thailand, Singapore, the Philippines, Malaysia, and the rest of South East Asia. Singapore is expected to grow at the highest CAGR during the forecast period, supported by the country's strong focus on healthcare infrastructure, significant numbers of pharmaceutical companies, and a projected increase in national health expenditure to $43 billion by 2030, making it a prime location for drug development and production.
Buy Now@ https://www.meticulousresearch.com/Checkout/81943636?utm_source=pdf&utm_medium=social&utm_campaign=product&utm_content=23-07-2024
About Meticulous Research®:
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.
Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research